Development and Commercialization of Licensed Products. As between Licensee and Kineta, 5.1.1 Prior to Licensee’s exercise of the Option, Kineta shall (i) have sole responsibility for, bear all costs for, developing and commercializing Licensed Products; (ii) have the sole right and authority to control all decisions related to the research, development and commercialization of Licensed Products (excepting Licensee activities as outlined in the Research and Early Development Plan); (iii) perform its Research and Early Development Plan activities and provide the results of same to Licensee using Diligent Efforts; and (iv) deliver any other documents (including regulatory filings) that Licensee reasonably requests to exercise the Option and Kineta-Genentech Exclusive Option and License Agreement 5.1.2 Following Licensee’s exercise of the Option, (i) Licensee shall have sole responsibility for, bear all costs for, researching, developing and commercializing Licensed Products; and (ii) Licensee shall have the sole right and authority to control all decisions related to the research, development and commercialization of Licensed Products. Following Licensee’s exercise of the Option, Licensee agrees to use Diligent Efforts to research, develop and commercialize at least one Licensed Product within the Field in the Territory. 5.1.3 Following Licensee’s exercise of the Option, K▇▇▇▇▇ shall use Diligent Efforts to complete the Technology Transfer as applicable.
Appears in 2 contracts
Sources: Exclusive Option and License Agreement (Yumanity Therapeutics, Inc.), Exclusive Option and License Agreement (Yumanity Therapeutics, Inc.)